Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02 | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.
MENU

Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02

Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02
Peptide News from Biotech and Pharma, Raw News October 3, 2017

... therapies to target solid tumors, announces that the US Patent and Trademark Office has granted US Patent no 9,775,892, Peptide mixture.

Email

support@boulderpeptide.org

s2Member®
loading...